Combinatorial approaches targeting the EGFR family and c-Met in SCCHN-Reference-Cited by-同舟云学术

Combinatorial approaches targeting the EGFR family and c-Met in SCCHN

Published:2021-01 Issue: Volume:112 Page:105074
ISSN:1368-8375
Container-title:Oral Oncology
language:en
Short-container-title:Oral Oncology

Author:

Wang Dongsheng,Lu Yue,Nannapaneni Sreenivas,Griffith Christopher C.,Steuer Conor,Qian Guoqing,Wang Xu,Chen Zhengjia,Patel Mihir,El-Deiry Mark,Shin Dong M.,He Xia,Chen Zhuo G.,Saba Nabil F.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Oral Surgery

Reference58 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray;Int J Cancer,2018

2. Hepatocyte growth factor/c-met signaling in head and neck cancer and implications for treatment;Rothenberger;Cancers,2017

3. Epidemiology, staging, and screening of head and neck cancer;Argiris;Cancer Treat Res,2003

4. Case-control study of human papillomavirus and oropharyngeal cancer;D'Souza;New Engl J Med,2007

5. High incidence of head and neck squamous cell carcinoma in patients with Fanconi anemia;Kutler;Arch Otolaryngol Head Neck Surg,2003

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel quinazoline-based dual EGFR/c-Met inhibitors overcoming drug resistance for the treatment of NSCLC: Design, synthesis and anti-tumor activity;Bioorganic Chemistry;2024-01

2. Advantages of the Combinatorial Molecular Targeted Therapy of Head and Neck Cancer—A Step before Anakoinosis-Based Personalized Treatment;Cancers;2023-08-24

3. Rationale for Cotargeting Hepatocyte Growth Factor and Epidermal Growth Factor Receptor in Recurrent/Metastatic Head and Neck Cancer;Journal of Clinical Oncology;2023-08-01

4. Randomized Phase II Trial of Ficlatuzumab With or Without Cetuximab in Pan-Refractory, Recurrent/Metastatic Head and Neck Cancer;Journal of Clinical Oncology;2023-08-01

5. Prediction of cancer nanomedicines self-assembled from meta-synergistic drug pairs;Journal of Controlled Release;2023-08